Relative risk and attributable risk proportion for anti-TB treatment between ATLI and non-ATLI anti-TB treatment cases.<sup>a</sup>
- Penghui Shang (348736)
- Yinyin Xia (348739)
- Feiying Liu (348742)
- Xiaomeng Wang (348745)
- Yanli Yuan (348748)
- Daiyu Hu (348751)
- Dehua Tu (348754)
- Yixin Chen (64217)
- Peiyuan Deng (348756)
- Shiming Cheng (348758)
- Lin Zhou (141050)
- Yu Ma (111665)
- Lizhen Zhu (348759)
- Weiwei Gao (51947)
- Hongyuan Wang (348760)
- Dafang Chen (80001)
- Li Yang (6520)
- Pingping He (348761)
- Shanshan Wu (348762)
- Shaowen Tang (285536)
- Xiaozhen Lv (348763)
- Zheng Shu (348764)
- Yuan Zhang (41832)
- Zhirong Yang (348765)
- Yan Chen (4308)
- Na Li (6550)
- Feng Sun (72641)
- Xiaoting Li (348766)
- Yingjian He (348767)
- Paul Garner (7861)
- Siyan Zhan (80002)
Publication date
February 2013
DOIAbstract
a<p>Abbreviation used in table: TB, tuberculosis; ATLI, Anti-tuberculosis Drug Induced Liver Injury; RR, relative risk; AR%: attributable risk proportion.</p>b<p>Intensive treatment phase: the number of patients was 4292, because 12 patients missed data.</p>c<p>Smear result at 2 months: the number of patients was 4259, because 45 patients missed smear examination.</p>d<p>AR%: it is the percent of the incidence of an outcome in the exposed that is due to the exposure.</p>e<p>Unsuccessful outcomes: A sum of treatment failure, died, default and transfer out.</p>f<p>Successful outcomes: A sum of cure and treatment completed.</p
Add to ORKG